IPIX Milestones, Clinical Trials, Recent Articles,
Post# of 72440
(Total Views: 1409)
Posted On: 02/10/2018 2:50:13 PM
IPIX Milestones, Clinical Trials, Recent Articles, Corporate Overview, Patents
Potential Milestones (Q1)
1. Prurisol - Topline Data (Phase 2b)
2. B-OM - Breakthrough Therapy Designation
Past Milestones
Kevetrin
- Positive primary endpoint (Phase 2a)
http://www.ipharminc.com/press-release/2018/2...3-observed
- Highly encouraging preliminary data (Phase 2a)
http://www.ipharminc.com/press-release/2017/1...ncer-trial
- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/1...e-patients
- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/1...ian-cancer
- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/1...tic-cancer
- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma
- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma
Brilacidin
- B-OM positive secondary endpoint (Phase 2)
http://www.ipharminc.com/press-release/2018/1...ositis-som
- B-OM positive top-line data (Phase 2)
http://www.ipharminc.com/press-release/2017/1...r-patients
- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7...brilacidin
- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/1...daptomycin
- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/1...n-from-fda
- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/1...-mucositis
- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/1...infections
- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/1...oot-ulcers
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
Prurisol
- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/1...y-endpoint
- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/1...ical-trial
- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/1...iasis-drug
Clinical Trials
1. K-OC (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT030427...amp;rank=1
2. P (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
3. B-OM (Phase 2, Completed )
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. P (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=4
5. P (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT029493...amp;rank=5
6. B-ABSSSI (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=6
7. K (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=7
8. B-UP (Phase 2 POC, Completed )
http://www.ipharminc.com/press-release/2016/1...-proctitis
Pipeline
Recent Articles
- A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug: Five Companies That Want It
http://www.baystreet.ca/stockstowatch/2658/A-...at-Want-It
- Innovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year End
https://seekingalpha.com/article/4088788-inno...n-year-end
- 2017 Q3 Conference Call Transcript
https://seekingalpha.com/article/4080068-inno...transcript
- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellc...transcript
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
Corporate Overview
- 2018 Biotech Showcase
https://static1.squarespace.com/static/571535...erview.pdf
- BioCentury NewsMakers Conference
https://static1.squarespace.com/static/571535...ep2017.pdf
- Drug Discovery and Therapy World Congress
https://static1.squarespace.com/static/571535...ul2017.pdf
Patents
- Kevetrin
https://www.google.com/patents/US8338454
- Brilacidin
https://www.sec.gov/Archives/edgar/data/13552...ex1037.htm
https://www.google.com/patents/US20160243117
https://www.google.com/patents/EP2709619A2
- Prurisol
https://www.google.com/patents/WO2013103601A1
MP Advisors Report
https://drive.google.com/file/d/0Bz15O4eaX-as...hENFk/view
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
Potential Milestones (Q1)
1. Prurisol - Topline Data (Phase 2b)
2. B-OM - Breakthrough Therapy Designation
Past Milestones
Kevetrin
- Positive primary endpoint (Phase 2a)
http://www.ipharminc.com/press-release/2018/2...3-observed
- Highly encouraging preliminary data (Phase 2a)
http://www.ipharminc.com/press-release/2017/1...ncer-trial
- Positive primary endpoint and p21 data (Phase 1)
http://www.ipharminc.com/press-release/2016/1...e-patients
- Orphan drug designation for ovarian cancer
http://www.ipharminc.com/press-release/2016/1...ian-cancer
- Orphan drug designation for pancreatic cancer
http://www.ipharminc.com/press-release/2016/1...tic-cancer
- Orphan drug designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma
- Rare pediatric disease designation for retinoblastoma
http://www.ipharminc.com/press-release/2016/1...noblastoma
Brilacidin
- B-OM positive secondary endpoint (Phase 2)
http://www.ipharminc.com/press-release/2018/1...ositis-som
- B-OM positive top-line data (Phase 2)
http://www.ipharminc.com/press-release/2017/1...r-patients
- B-UP positive top-line data (Phase 2 POC)
http://www.ipharminc.com/press-release/2017/7...brilacidin
- B-ABSSSI positive top-line data (Phase 2b)
http://www.ipharminc.com/press-release/2016/1...daptomycin
- QIDP designation for B-ABSSSI
http://www.ipharminc.com/press-release/2016/1...n-from-fda
- Fast track designation for B-OM
http://www.ipharminc.com/press-release/2016/1...-mucositis
- MTA extension for prophylactic testing in implanted devices
http://www.ipharminc.com/press-release/2016/1...infections
- Formulation stable at room temperature
http://www.ipharminc.com/press-release/2016/1...oot-ulcers
- American Society for Microbiology journal publication
http://aac.asm.org/content/early/2014/06/11/A...#corresp-1
Prurisol
- Positive top-line data (Phase 2a)
http://www.ipharminc.com/press-release/2016/1...y-endpoint
- Positive primary endpoint (Phase 1)
http://www.ipharminc.com/press-release/2016/1...ical-trial
- 505(b)(2) pathway
http://www.ipharminc.com/press-release/2016/1...iasis-drug
Clinical Trials
1. K-OC (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT030427...amp;rank=1
2. P (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT021012...amp;rank=2
3. B-OM (Phase 2, Completed )
https://clinicaltrials.gov/ct2/show/NCT023243...amp;rank=3
4. P (Phase 2a, Completed )
https://clinicaltrials.gov/ct2/show/NCT024944...amp;rank=4
5. P (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT029493...amp;rank=5
6. B-ABSSSI (Phase 2b, Completed )
https://clinicaltrials.gov/ct2/show/NCT020523...amp;rank=6
7. K (Phase 1, Completed )
https://clinicaltrials.gov/ct2/show/NCT016640...amp;rank=7
8. B-UP (Phase 2 POC, Completed )
http://www.ipharminc.com/press-release/2016/1...-proctitis
Pipeline
Recent Articles
- A Billion Dollar Market Just Waiting for a New Oral Mucositis Drug: Five Companies That Want It
http://www.baystreet.ca/stockstowatch/2658/A-...at-Want-It
- Innovation Pharmaceuticals Stock May Be A Triple-Crown Winner With Brilacidin By Year End
https://seekingalpha.com/article/4088788-inno...n-year-end
- 2017 Q3 Conference Call Transcript
https://seekingalpha.com/article/4080068-inno...transcript
- 2017 Q1 Conference Call Transcript
http://seekingalpha.com/article/4023682-cellc...transcript
- Interview with New Cellceutix President Dr A Bertolino
http://seekingalpha.com/article/3988240-inter...-bertolino
- Cellceutix Pipeline Continues to Hit Milestone After Milestone
https://www.streetwisereports.com/pub/na/cell...-milestone
- A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
http://www.thelifesciencesreport.com/pub/na/a...-jorgensen
Corporate Overview
- 2018 Biotech Showcase
https://static1.squarespace.com/static/571535...erview.pdf
- BioCentury NewsMakers Conference
https://static1.squarespace.com/static/571535...ep2017.pdf
- Drug Discovery and Therapy World Congress
https://static1.squarespace.com/static/571535...ul2017.pdf
Patents
- Kevetrin
https://www.google.com/patents/US8338454
- Brilacidin
https://www.sec.gov/Archives/edgar/data/13552...ex1037.htm
https://www.google.com/patents/US20160243117
https://www.google.com/patents/EP2709619A2
- Prurisol
https://www.google.com/patents/WO2013103601A1
MP Advisors Report
https://drive.google.com/file/d/0Bz15O4eaX-as...hENFk/view
Abbreviations
K – Kevetrin
B – Brilacidin
P – Prurisol
OC – ovarian cancer
ABSSSI – acute bacterial skin and skin structure infections
OM – oral mucositis
UP – ulcerative proctitis
QIDP – qualified infectious disease product
(3)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼